Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0204 | 0.3836 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.0274 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0204 | 0.3836 | 1 |
Echinococcus granulosus | inositol monophosphatase 1 | 0.0036 | 0.0084 | 0.001 |
Schistosoma mansoni | inositol monophosphatase | 0.0036 | 0.0084 | 0.0515 |
Echinococcus multilocularis | neuropeptide receptor A26 | 0.048 | 1 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.0084 | 0.5 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.0274 | 1 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0036 | 0.0084 | 0.001 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0035 | 0.0073 | 0.5 |
Echinococcus granulosus | neuropeptide receptor A26 | 0.048 | 1 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.0084 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0204 | 0.3836 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0204 | 0.3836 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0204 | 0.3836 | 1 |
Echinococcus multilocularis | neuropeptide s receptor | 0.048 | 1 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0044 | 0.0274 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0204 | 0.3836 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.0274 | 0.0202 |
Loa Loa (eye worm) | inositol-1 | 0.0036 | 0.0084 | 0.0515 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.0274 | 0.0202 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.0084 | 0.5 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0204 | 0.3836 | 0.5 |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0035 | 0.0073 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.0274 | 0.0202 |
Schistosoma mansoni | inositol monophosphatase | 0.0036 | 0.0084 | 0.0515 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.0274 | 0.0202 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0036 | 0.0084 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0204 | 0.3836 | 0.5 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0044 | 0.0274 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0036 | 0.0084 | 0.5 |
Brugia malayi | Inositol-1 | 0.0036 | 0.0084 | 0.0515 |
Trichomonas vaginalis | hypothetical protein | 0.0204 | 0.3836 | 1 |
Onchocerca volvulus | 0.0035 | 0.0073 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.0274 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.